Dabigatran

From Drugs Prescribing Information
Jump to: navigation, search
Click on "►" to expand:

Contents

[edit] BRAND NAMES

[edit] STRUCTURE

Dabigatran.jpg

[edit] MECHANISM OF ACTION

[edit] INDICATIONS

Dabigatran is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (FDA)

[edit] DOSAGE

  • For patients with CrCl >30 mL/min: 150 mg orally, twice daily.
  • For patients with CrCl 15-30 mL/min: 75 mg orally, twice daily

[edit] CONTRAINDICATIONS

  • Active pathological bleeding
  • History of serious hypersensitivity reaction to Dabigatran
  • Mechanical prosthetic heart valve

[edit] WARNINGS AND PRECAUTIONS

  • Risk of bleeding: Dabigatran can cause serious and, sometimes, fatal bleeding. Promptly evaluate signs and symptoms of blood loss.
  • Bioprosthetic heart valves: Dabigatran use not recommended

[edit] INTERACTIONS

[edit] PREGNANCY AND LACTATION

[edit] SIDE EFFECTS

Most common adverse reactions (>15%) are gastritis-like symptoms and bleeding

[edit] RELATED LINKS

[edit] BIBLIOGRAPHY

[edit] REFERENCES